Harnessing machine learning for development of microbiome therapeutics

被引:49
作者
McCoubrey, Laura E. [1 ]
Elbadawi, Moe [1 ]
Orlu, Mine [1 ]
Gaisford, Simon [1 ,2 ]
Basit, Abdul W. [1 ]
机构
[1] UCL, UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England
[2] FabRx Ltd, Ashford, Kent, England
基金
英国工程与自然科学研究理事会;
关键词
microbiome; machine learning; artificial intelligence; drug product development; microbial therapeutics; clinical translation; pharmaceutical sciences; COVID-19; colonic drug delivery; personalized medicines; BIG DATA; GUT; PREDICTION; METABOLISM; BIOTRANSFORMATION; INTELLIGENCE; BACTERIA; DELIVERY;
D O I
10.1080/19490976.2021.1872323
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The last twenty years of seminal microbiome research has uncovered microbiota's intrinsic relationship with human health. Studies elucidating the relationship between an unbalanced microbiome and disease are currently published daily. As such, microbiome big data have become a reality that provide a mine of information for the development of new therapeutics. Machine learning (ML), a branch of artificial intelligence, offers powerful techniques for big data analysis and prediction-making, that are out of reach of human intellect alone. This review will explore how ML can be applied for the development of microbiome-targeted therapeutics. A background on ML will be given, followed by a guide on where to find reliable microbiome big data. Existing applications and opportunities will be discussed, including the use of ML to discover, design, and characterize microbiome therapeutics. The use of ML to optimize advanced processes, such as 3D printing and in silico prediction of drug-microbiome interactions, will also be highlighted. Finally, barriers to adoption of ML in academic and industrial settings will be examined, concluded by a future outlook for the field.
引用
收藏
页码:1 / 20
页数:20
相关论文
共 176 条
[1]   Emergence of 3D Printed Dosage Forms: Opportunities and Challenges [J].
Alhnan, Mohamed A. ;
Okwuosa, Tochukwu C. ;
Sadia, Muzna ;
Wan, Ka-Wai ;
Ahmed, Waqar ;
Arafat, Basel .
PHARMACEUTICAL RESEARCH, 2016, 33 (08) :1817-1832
[2]   The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future [J].
Allegretti, Jessica ;
Eysenbach, Lindsay M. ;
El-Nachef, Najwa ;
Fischer, Monika ;
Kelly, Colleen ;
Kassam, Zain .
INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) :1710-1717
[3]   Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose [J].
Allegretti, Jessica R. ;
Fischer, Monika ;
Sagi, Sashidhar, V ;
Bohm, Matthew E. ;
Fadda, Hala M. ;
Ranmal, Sejal R. ;
Budree, Shrish ;
Basit, Abdul W. ;
Glettig, Dean L. ;
de la Serna, Eva L. ;
Gentile, Amanda ;
Gerardin, Ylaine ;
Timberlake, Sonia ;
Sadovsky, Rotem ;
Smith, Mark ;
Kassam, Zain .
DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (06) :1672-1678
[4]  
[Anonymous], 2002, Guidelines for the evaluation of probiotics in food
[5]  
[Anonymous], 2020, THE EC, V13, pS5
[6]  
[Anonymous], 2020, EUPATHDB MICROBIOMED
[7]  
[Anonymous], COVID 19 PLUNGE GLOB
[8]  
Aulton M.E., 2018, Aulton's Pharmaceutics: The design and manufacture of medicines
[9]   3D printing: Principles and pharmaceutical applications of selective laser sintering [J].
Awad, Atheer ;
Fina, Fabrizio ;
Goyanes, Alvaro ;
Gaisford, Simon ;
Basit, Abdul W. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 586
[10]   3D Printed Tablets (Printlets) with Braille and Moon Patterns for Visually Impaired Patients [J].
Awad, Atheer ;
Yao, Aliya ;
Trenfield, Sarah J. ;
Goyanes, Alvaro ;
Gaisford, Simon ;
Basit, Abdul W. .
PHARMACEUTICS, 2020, 12 (02)